BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
Investment Companies
Investment Companies
Investment Companies
Investment Companies
Claude Mikkelsen
Director of IR
Daniel Koller
Head of investment management
Dr Silvia Siegfried-Schanz
Director of IR
Erich Hunziker
Chairman
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 5.5 | 10.1 | (5.6) |
Relative | (0.1) | 2.3 | (1.7) |
52 week high/low | CHF70.1/CHF51.0 |
According to BB Biotech’s (BION) investment team, the biotech industry has never looked in such a good position. Following a sell-off in the last 18 months, a combination of fundamental industry strength and discounted valuations has recently attracted investors to return to the biotech market. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks) of what the investment manager, Bellevue Asset Management, believes to be best-in-class biotech growth opportunities. The BION team continues to focus on its core portfolio of biotech staples, such as Moderna, blended with undiscovered, innovative companies, bringing new technologies.
Get access to the very latest content matched to your personal investment style.